VEGF inhibition: insights from preclinical and clinical studies

Cell Tissue Res. 2009 Jan;335(1):261-9. doi: 10.1007/s00441-008-0675-8. Epub 2008 Sep 3.

Abstract

Angiogenesis, the growth of new blood vessels, is required for a variety of normal proliferative processes. Furthermore, angiogenesis is well established as also playing an important role in neoplastic growth and metastasis. Numerous regulators of angiogenesis have been identified and characterized over the last few decades. Among these, vascular endothelial growth factor (VEGF)-A appears especially important in several pathophysiological processes. Several VEGF inhibitors have been approved, by the US Food and Drug Administration, for the treatment of tumors or age-releted macular degeneration. This review examines the various mouse tumor models in which VEGF inhibitors have been tested and the lessons learned from these studies.

Publication types

  • Review

MeSH terms

  • Animals
  • Disease Models, Animal
  • Humans
  • Macular Degeneration / drug therapy
  • Macular Degeneration / metabolism
  • Macular Degeneration / physiopathology
  • Mice
  • Neoplasm Metastasis
  • Neoplasms / blood supply*
  • Neoplasms / drug therapy*
  • Neoplasms / metabolism
  • Neoplasms / physiopathology
  • Neovascularization, Pathologic / drug therapy*
  • Neovascularization, Pathologic / metabolism
  • Neovascularization, Pathologic / physiopathology
  • United States
  • United States Department of Agriculture
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors*
  • Vascular Endothelial Growth Factor A / metabolism

Substances

  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A